HAYWARD, Calif. — Impax Laboratories named Paul M. Bisaro its president and CEO, as well as the company’s board of directors.
Bisaro succeeds J. Kevin Buchi, who has served as interim president and CEO since December. Bisaro, 56, has 25 years of generic and branded pharmaceutical experience. He previously served as executive chairman of Allergan, and president, CEO and chairman of the board of Actavis.
"I am excited about the opportunity to lead Impax to its full potential in a rapidly changing environment," said Bisaro. "Impax has a strong reputation for its drug delivery, formulation and product development capabilities. We will continue to focus on developing high-quality products that meet the unique needs of our patients. Combining our R&D priorities with providing best in class customer service will provide additional value to our customers and deliver value for our shareholders.
Bisaro currently serves on the board of directors of Allergan, Zoetis and on the board of visitors of the Catholic University of America's Columbus School of Law. He also served as chairman of the board of the Generic Pharmaceutical Association, (now the Association for Accessible Medicines) in 2010 and 2011.
Impax Laboratories is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products.